<DrugInformationSummary id="CDR0000801597"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about daratumumab and hyaluronidase-fihj
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/daratumumabandhyaluronidase-fihj">Daratumumab and Hyaluronidase-fihj</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000795698">daratumumab and hyaluronidase-fihj</TerminologyLink><GlossaryLink ref="CDR0000801557">daratumumab and hyaluronidase</GlossaryLink><USBrandNames><USBrandName>Darzalex Faspro</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>DAYR-uh-TOOM-yoo-mab … HY-al-yoo-RAH-nih-days</TermPronunciation><MediaLink ref="CDR0000802719" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000804355" type="audio/mpeg" alt="" language="es" id="_6"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Daratumumab and Hyaluronidase-fihj</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_9"><Title>Use in Cancer</Title>                                                              
  <Para id="_10">Daratumumab and hyaluronidase-fihj
         is approved to be used alone or with other drugs to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_11">
   <ListItem><Strong>light-chain <GlossaryTermRef href="CDR0000045507" dictionary="Cancer.gov" audience="Patient">amyloidosis</GlossaryTermRef></Strong> that is newly diagnosed. It is used with <GlossaryTermRef href="CDR0000269133" dictionary="Cancer.gov" audience="Patient">bortezomib</GlossaryTermRef>,
<GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045262" dictionary="Cancer.gov" audience="Patient">dexamethasone</GlossaryTermRef>.¹</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef></Strong>: <ItemizedList Style="bullet" id="_8"><ListItem>For newly diagnosed cancer,  it is used:<ItemizedList Style="bullet" id="_14"><ListItem>with bortezomib,  dexamethasone, and either <GlossaryTermRef href="CDR0000045458" dictionary="Cancer.gov" audience="Patient">thalidomide</GlossaryTermRef> or lenalidomide in patients who can receive an <GlossaryTermRef href="CDR0000270733" dictionary="Cancer.gov" audience="Patient">autologous stem cell transplant</GlossaryTermRef></ListItem><ListItem> with bortezomib, <GlossaryTermRef href="CDR0000045957" dictionary="Cancer.gov" audience="Patient">melphalan</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> or with <GlossaryTermRef href="CDR0000393761" dictionary="Cancer.gov" audience="Patient">lenalidomide</GlossaryTermRef> and dexamethasone in patients who cannot receive an autologous stem cell transplant</ListItem></ItemizedList></ListItem><ListItem>For cancer that has come back or did not respond to treatment, it is used:<ItemizedList Style="bullet" id="_7"><ListItem>with dexamethasone and either lenalidomide or bortezomib in patients who have received at least one therapy</ListItem><ListItem>with <GlossaryTermRef href="CDR0000589401" dictionary="Cancer.gov" audience="Patient">pomalidomide</GlossaryTermRef> and dexamethasone in patients who have received at least one therapy that included lenalidomide and a proteasome inhibitor</ListItem><ListItem>with <GlossaryTermRef href="CDR0000737706" dictionary="Cancer.gov" audience="Patient">carfilzomib</GlossaryTermRef> and dexamethasone in patients who have received one to three types of therapy</ListItem><ListItem>alone in patients who have already received at least three types of therapy that included a <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef>  and an <GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">immunomodulating agent</GlossaryTermRef> or whose cancer did not respond to a proteasome inhibitor and an immunomodulatory agent</ListItem></ItemizedList> 

</ListItem></ItemizedList></ListItem>
   
   </ItemizedList>
  <Para id="_15">¹This use is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that daratumumab and hyaluronidase-fihj provides a clinical benefit in these patients.</Para><Para id="_12">Daratumumab and hyaluronidase-fihj is a form of <GlossaryTermRef href="CDR0000776992" dictionary="Cancer.gov" audience="Patient">daratumumab</GlossaryTermRef> that is given as a <GlossaryTermRef href="CDR0000045914" dictionary="Cancer.gov" audience="Patient">subcutaneous</GlossaryTermRef> <GlossaryTermRef href="CDR0000044678" dictionary="Cancer.gov" audience="Patient">injection</GlossaryTermRef>. This form can be given in less time than daratumumab, which is given as an <GlossaryTermRef href="CDR0000045738" dictionary="Cancer.gov" audience="Patient">infusion</GlossaryTermRef>. For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for <DrugRef href="CDR0000777063" url="/about-cancer/treatment/drugs/daratumumab">Daratumumab</DrugRef>.</Para><Para id="_13">Daratumumab and hyaluronidase-fihj
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Daratumumab and Hyaluronidase-fihj</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795698">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.31">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a620040.html">Daratumumab and Hyaluronidase-fihj</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.32"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.33">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C156401">Find Clinical Trials for Daratumumab And Hyaluronidase-fihj</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2020-05-14</DateFirstPublished><DateLastModified>2024-07-31</DateLastModified></DrugInformationSummary>
